ArriVent BioPharma AVBP 深 沪
等待开盘 11-06 09:30:00 美东时间
12.23
-1.260
-9.34%
华盛通- 最 高13.50
- 今 开13.39
- 成交量 110.19万股
- 最 低 12.18
- 昨 收 13.49
- 总市值 6.03亿
- 52周最高 35.83
- 市盈率 静 --
- 换手率 2.23%
- 52周最低 11.36
- 委 比 -51.08%
- 总股本 4930.77万
- 历史最高 36.37
- 量 比 0.89
- 振 幅 9.79%
- 历史最低 11.36
- 每 手 1
- 风险率 5.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股前瞻 | 加息概率仅7%！美联储利率决议凌晨2点来袭；强劲财报“带飞”股价！SK海力士盘前飙涨逾7%
加息概率仅7%！美联储利率决议凌晨2点来袭；强劲财报“带飞”股价！SK海力士盘前飙涨逾7%；Robinhood绩后跌近7%，微软、谷歌盘后放榜>>
10-28 20:25
美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
10-28 12:30
Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
10-27 21:29
ArriVent BioPharma shares are trading lower. The company announced Phase 1 results for ARR-217.
ArriVent BioPharma shares are trading lower. The company announced Phase 1 results for ARR-217.
10-27 01:16
ArriVent highlights firmonertinib Phase 1b lung cancer data
The latest update is out from ArriVent BioPharma, Inc. ( ($AVBP) ). On October ...
10-19 20:29
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics appoints Kristine Peterson and Lonnel Coats to its Board of Directors, adding extensive commercial and product launch experience ahead of the December 22 PDUFA target date for lorundrostat, a treatment for uncontrolled or resistant hypertension. Both executives bring deep expertise in launching and commercializing therapies, particularly in cardiovascular and metabolic disease. Peterson, with over three decades in biopharma...
10-19 20:05
美股大行评级 | Evercore维持SpaceX"跑赢大市"评级！目标价从230美元升至275美元
今日重点评级关注：Leerink Partners：维持First Tracks"跑赢大市"评级，目标价从70美元升至90美元；Keybanc：维持Absci"超配"评级，目标价从16美元升至20美元
10-19 18:42
BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target
BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.
10-17 02:21
美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
